Covered recipient · General Payments record
TODD ADAM GERSTEN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$5,196.26
259 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $4,797.17 | 255 |
| Long term medical supply or device loan | $299.10 | 3 |
| Education | $99.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 3 of 6; records 101–150 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TODD ADAM GERSTEN
NPI 1962408047 · CMS profile ID 88583
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
WELLINGTON, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 6; records 101–150 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962408047?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962408047?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962408047?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- TODD ADAM GERSTEN, NPI 1962408047, CMS profile ID 88583, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1962408047?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
259 matching records · $5,196.26 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 259.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $28.97 | 08/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050649413 | CMS |
| Novartis Pharmaceuticals Corporation | $13.35 | 08/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986063 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.35 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025013009 | CMS |
| BeiGene USA, Inc. | $21.40 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051178483 | CMS |
| Ipsen Biopharmaceuticals, Inc | $25.26 | 07/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045413265 | CMS |
| PFIZER INC. | $18.81 | 07/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049180675 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.43 | 07/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014920641 | CMS |
| GlaxoSmithKline, LLC. | $17.54 | 07/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001481261 | CMS |
| Cumberland Pharmaceuticals, Inc. | $20.07 | 07/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052116107 | CMS |
| Mirati Therapeutics, Inc. | $28.17 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057991325 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.84 | 07/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024983957 | CMS |
| Novartis Pharmaceuticals Corporation | $15.20 | 07/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986071 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.59 | 07/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024997593 | CMS |
| SOBI, INC | $26.06 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038111005 | CMS |
| Merck Sharp & Dohme LLC | $29.31 | 07/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048921495 | CMS |
| Exelixis Inc. | $16.50 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044579503 | CMS |
| Novartis Pharmaceuticals Corporation | $19.50 | 07/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986061 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.02 | 07/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014920609 | CMS |
| Novartis Pharmaceuticals Corporation | $0.41 | 07/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986053 | CMS |
| Novartis Pharmaceuticals Corporation | $13.53 | 07/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986057 | CMS |
| Rigel Pharmaceuticals, Inc. | $28.68 | 07/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033408833 | CMS |
| ImmunoGen, Inc. | $18.90 | 07/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017253219 | CMS |
| Janssen Biotech, Inc. | $17.86 | 07/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988361003 | CMS |
| ABBVIE INC. | $20.41 | 06/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997335255 | CMS |
| Seagen Inc. | $22.15 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995659731 | CMS |
| Janssen Biotech, Inc. | $14.11 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988361073 | CMS |
| Rigel Pharmaceuticals, Inc. | $7.50 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033411535 | CMS |
| Rigel Pharmaceuticals, Inc. | $2.94 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033411559 | CMS |
| GlaxoSmithKline, LLC. | $17.81 | 06/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001480474 | CMS |
| Agios Pharmaceuticals, Inc. | $16.85 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056204093 | CMS |
| Janssen Biotech, Inc. | $16.15 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988361083 | CMS |
| Novartis Pharmaceuticals Corporation | $13.05 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986049 | CMS |
| Astellas Pharma US Inc | $17.27 | 06/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034220435 | CMS |
| Deciphera Pharmaceuticals Inc. | $20.33 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053717927 | CMS |
| Merck Sharp & Dohme LLC | $28.42 | 06/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048502159 | CMS |
| Astellas Pharma US Inc | $18.90 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034185031 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.02 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025057245 | CMS |
| Celgene Corporation | $0.58 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014920591 | CMS |
| Celgene Corporation | $23.25 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014920599 | CMS |
| Astellas Pharma US Inc | $24.10 | 06/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034173011 | CMS |
| Novartis Pharmaceuticals Corporation | $19.30 | 06/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991986045 | CMS |
| Genentech USA, Inc. | $22.48 | 06/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040584377 | CMS |
| EMD Serono, Inc. | $20.00 | 06/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032338173 | CMS |
| PFIZER INC. | $23.03 | 06/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049364399 | CMS |
| ABBVIE INC. | $27.95 | 06/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997335253 | CMS |
| GENZYME CORPORATION | $17.76 | 06/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049894763 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.26 | 06/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025055219 | CMS |
| Janssen Biotech, Inc. | $21.81 | 06/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988361035 | CMS |
| NOVARTIS PHARMACEUTICALS CORPORATION | $99.70 | 05/31/2023 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993422847 | CMS |
| Kite Pharma, Inc. | $17.60 | 05/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025269247 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $404,044.23 | 552 |
| PY2024 | Principal investigator | $164,517.02 | 28 |
| PY2023 | Principal investigator | $613,998.34 | 87 |
| PY2022 | Principal investigator | $850,123.27 | 63 |
| PY2021 | Principal investigator | $605,575.32 | 92 |
| PY2020 | Principal investigator | $284,690.72 | 129 |
| PY2019 | Principal investigator | $435,198.17 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
552 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,000.00 | 12/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) | No dispute reported | 06/30/2026 | 1185540605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638632 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638646 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638648 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638662 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638688 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638700 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 12/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,600.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175324070 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 12/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,232.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329121 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175321110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 12/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175322370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 12/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175322840 |
| Principal investigator 1 | Janssen Research & Development, LLC | $562.50 | 12/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175326210 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,022.00 | 12/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638467 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638576 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638582 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 11/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,818.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,426.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $170.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328837 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 11/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,780.00 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322832 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/20/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328942 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175320793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,200.00 | 10/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175321205 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,252.00 | 10/06/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639320 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639324 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639334 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639336 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639338 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639342 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639348 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639350 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639352 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639354 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639356 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639360 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639364 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639372 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639374 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639388 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639404 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639418 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639420 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 09/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 09/29/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326336 |
| Principal investigator 1 | Astellas Pharma Global Development | $354.00 | 09/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175328037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 09/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175329424 |
| Principal investigator 1 | Astellas Pharma Global Development | $183.67 | 09/01/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185990 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639194 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639196 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639200 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639206 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639208 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639232 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639266 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639270 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 08/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639304 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 08/25/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175325594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,812.67 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,500.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175322191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,517.33 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175324792 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | No dispute reported | 06/30/2026 | 1175326480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639062 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639064 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639066 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639068 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639070 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639072 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639074 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639076 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639078 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639080 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639088 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639090 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639092 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639096 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639102 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639110 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639114 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 07/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639184 |
| Principal investigator 1 | Astellas Pharma Global Development | $250.00 | 07/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185952 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,987.67 | 07/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175326898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,000.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327569 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,430.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175329553 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $1,151.26 | 07/03/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute, Llc | A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther | No dispute reported | 06/30/2026 | 1236530668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638962 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638964 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638968 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638970 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638976 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638980 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638984 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638986 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638990 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638994 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638996 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638998 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639000 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639006 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639008 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639010 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639012 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639014 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639016 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639018 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639020 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639022 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639026 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639028 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639030 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639032 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639036 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639038 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639040 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639042 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639044 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639046 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639048 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639050 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639052 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639054 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639056 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639058 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 06/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220639060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175325750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,500.00 | 06/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy | No dispute reported | 06/30/2026 | 1175325793 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,350.00 | 05/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185540609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638846 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638848 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638856 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638860 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638872 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638880 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638896 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638898 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638900 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638902 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638906 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638908 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638910 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638912 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638914 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638916 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638920 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638922 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638924 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638928 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638930 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638932 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638934 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638936 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638938 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638940 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638942 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638944 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638946 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638948 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638950 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638954 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638956 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638958 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 05/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638960 |
| Principal investigator 1 | Astellas Pharma Global Development | $250.00 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185948 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,759.40 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185540601 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $82,334.84 | 05/01/2025 | Non-covered Recipient Entity Sarah Cannon Research Institute | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235993987 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $39,415.14 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185540607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638784 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 04/30/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638836 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185956 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185958 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185960 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185962 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185964 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185966 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185968 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185970 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185972 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185974 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185976 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185978 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185980 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185982 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185984 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 04/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185986 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,455.48 | 04/01/2025 | Non-covered Recipient Entity SARAH CANNON CANCER INSTITUTE AT HDH | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176545043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638728 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638754 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638768 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638770 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.51 | 03/31/2025 | Non-covered Recipient Entity Florida Cancer Specialists And Research Institute West Palm Beach | An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy | No dispute reported | 06/30/2026 | 1220638780 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 03/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185944 |
| Principal investigator 1 | Astellas Pharma Global Development | $588.00 | 03/27/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185946 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,400.50 | 02/25/2025 | Non-covered Recipient Entity Florida Cancer Specialists | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235997365 |
| Principal investigator 1 | Astellas Pharma Global Development | $250.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234185950 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $325.00 | 01/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS | A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer | No dispute reported | 06/30/2026 | 1190305005 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,300.00 | 01/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer | No dispute reported | 06/30/2026 | 1190304463 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,305.95 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185540603 |